Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation
- PMID: 15698628
- DOI: 10.1016/j.expneurol.2004.11.005
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation
Abstract
We have studied the regulation of BDNF mRNA expression in the corticostriatal and nigrostriatal systems following neurotoxin ablation of striatal targets induced by quinolinic acid (QA) or 2S:2'R:3'R:-2-(2'3'-dicarboxycyclopropyl)glycine (DCG-IV) injections. Striatal lesions were verified by quantifying the loss of glutamic acid decarboxylase (GAD) mRNA expression. Levels of BDNF mRNA were analyzed at 6, 12, and 24 h postlesion. Both lesions paradigms highly induced BDNF mRNA in the ipsilateral cerebral cortex at 6 and 12 h postlesion to drop to control levels at 24 h postlesion. These inductions were mostly restricted to cortical layers II/III and V and ipsilateral insular and piriform cortices, which provide the main cortical inputs to the striatum. Analysis of neuronal activation on these areas demonstrated high levels of cFos mRNA in response to the excitotoxic striatal lesions. Dual labeling of cFos and BDNF mRNAs demonstrated a positive correlation between cortical neuronal activation and expression of BDNF mRNA. Consequently, expression of BDNF in cortical areas projecting to striatum is dependent on both target integrity and neuronal activity. Regulation of BNDF mRNA in substantia nigra, the second major source of BDNF to striatal cells, highly differed from that seen in cerebral cortex. Analysis of cellular expression alone or in combination of BDNF, cFos, tyrosine hydroxylase and GAD mRNAs demonstrated that expression of BDNF in substantia nigra is dependent on target integrity and independent of neuronal activity. In addition, we have studied regulatory mechanisms of BDNF mRNA in the subthalamic nucleus.
Similar articles
-
Expression of BDNF mRNA in substantia nigra is dependent on target integrity and independent of neuronal activation.J Neurochem. 2003 Nov;87(3):709-21. doi: 10.1046/j.1471-4159.2003.02041.x. J Neurochem. 2003. PMID: 14535953
-
Upregulation of BDNF mRNA and trkB mRNA in the nigrostriatal system and in the lesion site following unilateral transection of the medial forebrain bundle.Exp Neurol. 2000 Jan;161(1):38-48. doi: 10.1006/exnr.1999.7243. Exp Neurol. 2000. PMID: 10683272
-
Developmental regulation of BDNF and NT-3 expression by quinolinic acid in the striatum and its main connections.Exp Neurol. 2000 Sep;165(1):118-24. doi: 10.1006/exnr.2000.7451. Exp Neurol. 2000. PMID: 10964490
-
Cellular principles underlying normal and pathological activity in the subthalamic nucleus.Curr Opin Neurobiol. 2006 Dec;16(6):621-8. doi: 10.1016/j.conb.2006.10.003. Epub 2006 Nov 3. Curr Opin Neurobiol. 2006. PMID: 17084618 Review.
-
Pathophysiology of L-dopa-induced dyskinesias.Mov Disord. 1999;14 Suppl 1:4-8. Mov Disord. 1999. PMID: 10493397 Review. No abstract available.
Cited by
-
Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.Exp Neurol. 2015 Apr;266:11-21. doi: 10.1016/j.expneurol.2015.02.005. Epub 2015 Feb 12. Exp Neurol. 2015. PMID: 25681575 Free PMC article.
-
Laser-mediated cell ablation during post-implantation mouse development.Dev Dyn. 2013 Oct;242(10):1202-9. doi: 10.1002/dvdy.24017. Epub 2013 Sep 2. Dev Dyn. 2013. PMID: 23873840 Free PMC article.
-
Ethanol-BDNF interactions: still more questions than answers.Pharmacol Ther. 2008 Apr;118(1):36-57. doi: 10.1016/j.pharmthera.2008.01.003. Epub 2008 Feb 2. Pharmacol Ther. 2008. PMID: 18394710 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources